SABS icon

SAB Biotherapeutics
SABS

Overview Fund Trends Analyst Outlook Journalist POV
Buy
Hold
Sell

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
Avg. target
$9.33
272% upside
High target

3 analyst ratings

positive
0  neutral
0%
negative
Analyst & Firm Rating Price Target Upside
Downside 		Date
Chardan Capital
Chardan Capital
Keay Nakae
50% 1-yr SABS win rate
19 Sep ‘25 1 month ago
Leerink Partners
Leerink Partners
100% 1-yr SABS win rate
17 Sep ‘25 1 month ago
HC Wainwright & Co
HC Wainwright & Co
Emily Bodnar
50% 1-yr SABS win rate
22 Jul ‘25 2 months ago